According to a study presented on cardiometabolic papers that were previously published in Circulation, assessment that used the WATCH-DM score, followed by N-terminal pro-B-type natriuretic peptide testing, identified approximately 90% of patients with diabetes who would benefit from an SGLT2 inhibitor to prevent heart failure. In a cohort of 6,293 participants (48% women; 77.7% without ASCVD), researchers looked at four one-step screening strategies: echocardiography-based diabetic cardiomyopathy testing, WATCH-DM risk score, NT-proBNP testing, and high-sensitivity cardiac troponin testing; the WATCH-DM and echocardiographic assessment identified the most participants as being high risk for incident heart failure.

Reference: Buzby S. Two-step screening could prevent heart failure in diabetes with no history of CVD. Healio. Published June 11, 2024. Accessed September 11, 2024. https://www.healio.com/news/cardiology/20240611/twostep-screening-could-prevent-heart-failure-in-diabetes-with-no-history-of-cvd